Stock code: 688276 Stock abbreviation: Baike Biological Announcement No.: 2024-022.

Changchun Baike Biotechnology Co., Ltd.

Announcement on the Listing and Circulation of Partial Restricted Shares in Initial Public Offering

the company's board of directors and all directors to ensure that the contents of this announcement does not exist any false records, misleading statements or major omissions, and the authenticity, accuracy and completeness of the contents of the legal responsibility.

Important Content Tips:

The type of stock listing is the initial restricted shares; the stock subscription method is offline, and the restricted period is 36 from the date of listing of Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as the "Company" or "Baike Bio") Months. The number of shares listed is 171,488,182.

The total number of shares listed in circulation is 171,488,182 shares.

The date of this stock listing is June 25, 2024.

Types of restricted shares in circulation 1. the listing

According to the "Agreement on Consent to Changchun Baike" issued by the China Securities Regulatory Commission on May 7, 2021

Approval of the Registration of the Initial Public Offering of Shares of Biotechnology Joint Stock Company "(Securities Regulatory License [2021] No. 1594), approving the application for registration of the Company's initial public offering of shares. The company's first public offering of RMB to the public

41,284,070 shares of shares (A shares) and will be available on the Shanghai Stock Exchange on June 25, 2021.

After the completion of the issuance, the total share capital is 412,840,698 shares, including 381,415,842 shares with limited sale conditions and 31,424,856 shares with unlimited sale conditions.

The restricted shares listed and circulated this time are part of the company's initial public offering of restricted shares, and the lock-up period is 36 months from the date of the company's initial public offering. The number of shareholders of restricted shares listed and circulated this time is 1, and the number of shares released and applied for listing and circulation is 171,488,182, accounting for 41.46 of the total share capital of the company.

It will be listed and circulated on June 25, 2024.

Changes in the number of shares of the 2. since the formation of the restricted shares listed in circulation

On March 18, 2024, the company held the 23rd meeting of the fifth board of directors and the fifth board of supervisors

Seventeen meetings to consider and adopt the first partial grant of the 2022 Restricted Stock Incentive Plan.

The bill on the achievement of the conditions of vesting during the vesting period. Upon completion of the first vesting period of the first grant of the Company's 2022 Restricted Stock Incentive Plan, the total number of shares of the Company increased from 412,840,698 to 413,657,598.

For details, please refer to the website of Shanghai Stock Exchange on April 26, 2024 (www.sse.com.cn)

The disclosed "Changchun Baike Biotechnology Co., Ltd. 2022 Restricted Stock Incentive Plan for the first grant of part of the first vesting period vesting results and share listing announcement" (Announcement No. 2024-018).

In addition to the above-mentioned changes in the number of share capital, from the formation of the company's initial public offering of restricted shares to the disclosure date of this announcement, the company has not undergone other changes in the number of share capital.

Commitments 3. the restricted shares in circulation in this listing

According to the Company's "Prospectus for Initial Public Offering and Listing on the CRE Board" and the "Announcement on Listing of the Initial Public Offering of Shares on the CRE Board", the commitments of the shareholders applying for the lifting of the share restriction regarding the restricted shares held by them are as follows:

Changchun High-tech Industry (Group) Co., Ltd., the controlling shareholder of the company, undertakes as follows:

"1. Within 36 months from the date of listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, the Company will not transfer or entrust others to manage the shares issued before the initial public offering directly and indirectly held by the Company (hereinafter referred to as" pre-IPO shares "), nor will Baike Bio repurchase such shares.

2. After the lock-up period of the company's shares held by the company expires, the company will earnestly abide by the relevant regulations of the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") and the stock exchange on shareholder reduction, and carefully formulate and disclose Stock reduction plan, and disclose the progress of the reduction in accordance with laws, regulations and the provisions of the stock exchange. If the Company reduces its holdings of pre-IPO shares after the expiration of the lock-up period, the Company will clarify and disclose the Company's control arrangements to ensure the Company's continued stable operation.

3. If the shares held by the enterprise before the initial public offering of Baike Bio are reduced within two years after the expiration of the lock-up period, the reduction price shall not be lower than the issue price. Within six months after the listing of 100 grams of biological shares, if the closing price of 100 grams of biological shares is lower than the issue price for 20 consecutive trading days, or the closing price at the end of six months after listing (if the day is not a trading day, it is the first trading day after that day) is lower than the issue price, the lock-up period of 100 grams of biological shares held by the enterprise will be automatically extended for six months. The above issue price refers to the issue price of Baike Bio's initial public offering. If there are ex-rights and ex-dividend events such as dividend distribution, share gift, capitalization of capital reserve, issuance of new shares, etc. after the listing of Baike Bio, the above issue price shall be treated as ex-rights and ex-dividend in accordance with relevant laws, regulations, normative documents and relevant provisions of the stock exchange.

4. Under any of the following circumstances, the Company undertakes not to reduce its shareholding in Baike Bio held by the Company:

(1) Baike Bio or the enterprise is suspected of securities and futures crimes, in the case of the China Securities Regulatory Commission.

During the period of investigation or investigation by the judicial organ, and less than six months after the administrative penalty decision or criminal judgment is made.

(2) The enterprise has been publicly reprimanded by the stock exchange for less than three months for violating the rules of the stock exchange.

(3) Other circumstances under which the CSRC may not reduce its holdings."

In addition to the above commitments, the shareholders of the restricted shares applying for listing have no other special commitments regarding the restricted sale of shares.

As of the date of disclosure of this announcement, the shareholders applying for the lifting of the share restriction strictly fulfill the corresponding commitments, and there is no situation that the failure to fulfill the relevant commitments will affect the listing and circulation of the restricted shares.

Occupancy of funds by 4. controlling shareholders and their related parties

The Company does not have any funds occupied by the controlling shareholder and its related parties.

Verification opinions of 5. intermediaries

Changes of (I) Intermediaries and Undertakers

CITIC Securities Co., Ltd. (hereinafter referred to as "sponsor" or "CITIC Securities"), as the sponsor and continuous supervision organization of the company's initial public offering and listing on the science and technology innovation board, originally appointed Mr. Zhu Shaohui and Ms. Dong Zhiru as the sponsor representatives of the company, responsible for the recommendation and continuous supervision of the initial public offering. In May 2024, Ms. Dong Zhiru's work was adjusted and she will no longer continue to serve as the sponsor representative of the company's continuous supervision. In order to ensure the orderly progress of the company's continuous supervision work, CITIC Securities now appoints Mr. Wang Chenchen to replace Ms. Dong Zhiru as the sponsor representative of the company's continuous supervision and will continue to perform the duties of continuous supervision. After the change of the sponsor representative, the sponsor representatives during the continuous supervision of the company's initial listing project are Mr. Zhu Shaohui and Mr. Wang Chenchen. Specific content

For details, please refer to the Company's disclosure on the website of the Shanghai Stock Exchange (www.sse.com.cn) on May 17, 2024.

Announcement of Changchun Baike Biotechnology Co., Ltd. on the replacement of the sponsor representative of continuous supervision (Announcement No. 2024-020).

Verification of (II) intermediaries

After verification, the sponsor believes that: as of the date of issuance of this verification opinion, the holders of restricted shares of Baike Bio have strictly complied with the commitments made in the initial public offering of shares of the company. The number of restricted shares listed and circulated and the time of listing and circulation are in compliance with the relevant provisions of the Measures for the Administration of Securities Issuance and Listing Sponsorship Business, the Rules for the Listing of Stocks on the Shanghai Stock Exchange's Science and Technology Board, and the Guidelines for the Self-Regulation of Listed Companies on the Shanghai Stock Exchange's Science and Technology Board No. 1-Standardized Operation. The sponsor agreed to the listing and circulation of the restricted shares of Baike Bio.

6. of the restricted shares in circulation in this listing

The total number of restricted shares in circulation (I) this listing is 171,488,182 shares, with a restricted period of 36 months.

The date of this listing and circulation of the (II) is June 25, 2024.

List of (III) restricted shares listed and circulated

Holding restricted shares remaining restricted

Order Shareholders holding restricted share capital sub-listed circulation.

Number of shares in total company

Number Name Quantity (shares) Quantity (shares)

Percentage (shares)

Changchun High-tech Products

1 Industry (Group) shares 171,488,182 41.46 171,488,182 0

Limited Company

Total 171,488,182 41.46 171,488,182 0

restricted shares listed circulation table:

No. Type of restricted shares Number of shares in circulation (shares)

1 Initial Restricted Shares 171,488,182

Total -171,488,182

7. Internet Announcement Annex

"Verification Opinions of CITIC Securities Co., Ltd. on the Listing and Circulation of Some Restricted Shares in the Initial Public Offering of Changchun Baike Biotechnology Co., Ltd."

It is hereby announced.

Board of Directors of Changchun Baike Biotechnology Co., Ltd.

June 15, 2024